Escalated thinking.

This editorial makes the observation that high-level data supporting the use of ADT for all intermediate and high risk prostate cancer fails to hold true for intermediate risk disease when (now standard) dose-escalation is employed. | Kollmeier, J Clin Oncol 2020

Comments

Popular Posts